Author

Cassie Dong

Observed names: C Dong, C. Dong

Institution: Vertex Pharmaceuticals (United States)

Observed institutions: Mayo Clinic, Manchester Academic Health Science Centre, Samsung Medical Center, University of Manchester, Medical University of Lodz, The Christie NHS Foundation Trust, Takeda (United States), Takeda Oncology (United States), University of Rochester, Vertex Pharmaceuticals (United States), University of Tennessee at Knoxville, Seagen (United States)

OpenAlex ID: A5012374629

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

2022 · Stephen M. Ansell, John Radford, et al. · New England Journal of Medicine · 347

PDF

Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

2024 · Stephen M. Ansell, David J. Straus, et al. · Journal of Clinical Oncology · 13

PDF

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.

2022 · Stephen M. Ansell, Joseph M. Connors, et al. · Journal of Clinical Oncology · 11

Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer

2021 · Sara Hurvitz, Linda Vahdat, et al. · Cancer Research · 11

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

2022 · Xiaofei Zhou, Ulka Vaishampayan, et al. · Investigational New Drugs · 9

PDF

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

2021 · Steven M. Horwitz, Kerry J. Savage, et al. · Blood · 7

353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer

2020 · S.A. Hurvitz, L.T. Vahdat, et al. · Annals of Oncology · 7

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

2025 · Eva Domingo-Domènech, Barbara Pro, et al. · Blood Cancer Journal · 5

PDF

Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1

2023 · Howland E. Crosswell, Ann S. LaCasce, et al. · Haematologica · 4

PDF

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

2021 · Howland E. Crosswell, Ann S. LaCasce, et al. · Journal of Clinical Oncology · 4

HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

2022 · David Straus, John Radford, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Abstract OT2-01-01: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer

2020 · Sara Hurvitz, Linda Vahdat, et al. · Cancer Research · 1

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

2026 · Eva Domingo-Domènech, Barbara Pro, et al. · Blood Cancer Journal

PDF

A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?

2024 · Yulia Sidi, Cassie Dong, et al. · Leukemia Research

Pb2351: Trial in Progress: a Phase 2, Multicentre Study of Brentuximab Vedotin With Chemotherapy in Frontline Treatment of Chinese Patients With Cd30-positive Peripheral T-cell Lymphomas

2023 · Yuqin Song, Helen Wu, et al. · HemaSphere

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

2022 · Martin Hutchings, Stephen M. Ansell, et al. · HemaSphere

Poster: HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

2022 · David Straus, John Radford, et al. · Clinical Lymphoma Myeloma & Leukemia

Brentuximab Vedotin With Chemotherapy in Adolescents and Young Adults (ayas) With Stage Iii or Iv Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 Echelon‐1 Study

2021 · H. E Crosswell, A. S. LaCasce, et al. · Hematological Oncology

PDF

Works count: 18

Citation count: 421

H-index: 7

I10-index: 4